DARE News and Press, Dare Bioscience Inc. From 05/11/23

2023-05-11 11:45:10 ET Dare Bioscience press release ( NASDAQ: DARE ): Q1 GAAP EPS of -$0.09. Cash and cash equivalents: $19.8 million at March 31, 2023. For further details see: Dare Bioscience GAAP EPS of -$0.09

2023-05-11 09:16:34 ET Dare Bioscience press release ( NASDAQ: DARE ): Q1 GAAP EPS of -$0.09 beats by $0.01 . Cash and cash equivalents: $19.8 million at March 31, 2023. For further details see: Dare Bioscience GAAP EPS of -$0.09 beats by $0.01

Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Clinical Study Topline Data XACIATO™ First Commercial Sale Ovaprene Pivotal Contraceptive Efficacy Study Initiation ...

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023, to review its financial results for t...

Phase 1 Thermography Study Quantitative Data Expected to Complement Patient Reported Outcome Data Collected in the Exploratory Phase 2b RESPOND At-Home Study Topline Data for the Exploratory Phase 2b RESPOND Study Anticipated in 2Q-2023 SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -...

SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will be presenting in the Keynote Forum of the Global Pharma & Drug D...

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, April 1...

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion at the Innovations in Women...

2023-04-10 10:48:10 ET A group of senior pharma executives, including Pfizer ( NYSE: PFE ) chief executive Albert Bourla, has come forward in support of the FDA after a Texas-based judge suspended the approval of abortion treatment mifepristone on Friday. Mifepristone, appro...

2023-04-03 08:16:44 ET OncoSec Medical ( ONCS ) -62% clinical data of the KEYNOTE-695 trial assessing TAVO EP in combination with KEYTRUDA (pembrolizumab) in patients with advanced melanoma refractory to anti-PD-1 treatment. Ascendis Pharma ( ASND ) -38% after FD...